Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 8/20 | 0.45 |
| ▸ | ADORA1 | P30542 | 3/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | MCL1 | Q07820 | 2/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | PKM | P14618 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
| ▸ | BCL2 | P10415 | 1/20 | 0.32 |
| ▸ | EPHB4 | P54760 | 1/20 | 0.31 |
| ▸ | DHFR | P00374 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23920929 | 0.90 | ADORA3 (0.46) | ADORA3ADORA1TDP1TP53ALDH1A1 | |
| SCHEMBL21396340 | 0.89 | ADORA3 (0.45) | ADORA3ADORA1TDP1TP53ALDH1A1 | |
| SCHEMBL23921009 | 0.89 | ADORA3 (0.44) | ADORA3ADORA1TDP1TP53ALDH1A1 | |
| SCHEMBL23920864 | 0.89 | ADORA3 (0.45) | ADORA3ADORA1TDP1TP53ALDH1A1 | |
| SCHEMBL23920998 | 0.88 | ADORA3 (0.48) | ADORA3ADORA1TDP1TP53ALDH1A1 | |
| SCHEMBL23921237 | 0.87 | ADORA3 (0.43) | ADORA3ADORA1TDP1TP53ALDH1A1 | |
| SCHEMBL23920938 | 0.86 | ADORA3 (0.42) | ADORA3ADORA1TDP1TP53 | |
| SCHEMBL23920903 | 0.86 | ADORA3 (0.48) | ADORA3ADORA1TDP1TP53ALDH1A1 | |
| SCHEMBL23921233 | 0.84 | ADORA3 (0.51) | ADORA3ADORA1TDP1TP53GAA | |
| SCHEMBL23920978 | 0.83 | ADORA3 (0.52) | ADORA3ADORA1TDP1TP53ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230242568-A1 | POLYMER LINKED MULTIMERS OF GUANOSINE-3', 5'-CYCLIC MONOPHOSPHATES | MIRECA MEDICINES GMBH (DE) | 2023-08-03 | — | — | US | disclosed |
| US-20220402964-A1 | NEW EQUATORIALLY MODIFIED POLYMER LINKED MULTIMERS OF GUANSINE-3', 5'-CYCLIC MONOPHOSPHATES | Graybug Vision, Inc. (US) | 2022-12-22 | — | — | US | disclosed |
| US-20210317156-A1 | NEW POLYMER LINKED MULTIMERS OF GUANOSINE-3', 5'-CYCLIC MONOPHOSPHATES | MIRECA MEDICINES GMBH (DE) | 2021-10-14 | — | — | US | disclosed |
| US-20190292214-A1 | NEW EQUATORIALLY MODIFIED POLYMER LINKED MULTIMERS OF GUANOSINE-3', 5'-CYCLIC MONOPHOSPHATES | MIRECA MEDICINES GMBH (DE) | 2019-09-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230242568-A1 | POLYMER LINKED MULTIMERS OF GUANOSINE-3', 5'-CYCLIC MONOPHOSPHATES | PRKG1, PRKG2, PRKAG3 | ADORA3 425/4885ADORA1 857/4885TDP1 669/4885 |
| US-20220402964-A1 | NEW EQUATORIALLY MODIFIED POLYMER LINKED MULTIMERS OF GUANSINE-3', 5'-CYCLIC MONOPHOSPHATES | PRKG1, PDE7A, PDE5A | ADORA3 463/4885ADORA1 764/4885TDP1 1141/4885 |
| US-20190292214-A1 | NEW EQUATORIALLY MODIFIED POLYMER LINKED MULTIMERS OF GUANOSINE-3', 5'-CYCLIC MONOPHOSPHATES | PDE7A, PRKG1, PDE4C | ADORA3 322/4885ADORA1 578/4885TDP1 1274/4885 |
| US-20210317156-A1 | NEW POLYMER LINKED MULTIMERS OF GUANOSINE-3', 5'-CYCLIC MONOPHOSPHATES | PRKG1, PRKG2, PDE7A | ADORA3 449/4885ADORA1 828/4885TDP1 690/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.